Solutia Reports Third Quarter 20...(P financial measures. Reconciliations o...)

Date:10/26/2009

P financial measures. Reconciliations of these measures to GAAP measures are included immediately below. Reconciliation of Income (Loss) Attributable to Solutia to Adjusted EBITDA from Continuing Operations Successor Successor --------- --------- Three Months Three Months Ended Ended September 30, September 30, (dollars in millions) 2009 2008 ---- ---- Net Income (Loss) Attributable to Solutia $29 $(7) Plus: Income Tax Expense 12 17 Interest Expense 31 42 Depreciation and Amortization 27 28 (Income) Loss from Discontinued Operations, net of tax - 28 Events affecting comparability, pre-tax: Reorganization items - - Other items (see below) 16 (1) Non-cash Stock Compensation Expense 4 3 Nylon Cost Overhang - 1 --- --- Adjusted EBITDA from Continuing Operations $119 $111 --- --- Successor Predecessor Successor Combined --------- ----------- --------- -------- Nine Months Two Months Seven Months Nine Months
'/>"/>

SOURCE Solutia Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26
Related biology technology :

1. Solutia Reports First Quarter 2009 Results
2. Solutia to Present at Deutsche Bank Small and Mid Cap Conference
3. Hanger Orthopedic Group, Inc. Reports an Increase of 30.4% in Earnings Per Share, to $0.30, for the Third Quarter 2009 and Raises Its 2009 Guidance
4. NuVasive Reports Third Quarter 2009 Financial Results
5. Raptor Pharmaceutical Reports Positive Interim Phase 2a Clinical Data in Non-Alcoholic Steatohepatitis (NASH)
6. Fibrocell Science, Inc. Reports Outcome of FDA Advisory Committee Meeting on Azfibrocel-T for Wrinkles
7. Pieris Reports Preclinical Development Progress of its Next Generation VEGF Antagonist
8. Peregrine Pharmaceuticals Reports Positive Results From Phase II Bavituximab Lung Cancer Trial
9. Tianyin Pharmaceutical Co., Inc. Reports Record Fiscal 2009 Financials With $7.9 Million in Net Income
10. Neogen Reports 18% Increase in Net Income, 12% Increase in Revenues
11. Sinobiopharma Reports Highlights From Audited Financial Results for the Fiscal Year Ended May 31, 2009